Price Action To Observe: Portola Pharmaceuticals Inc Declines Again; Strong Momentum for Sellers

Price Action To Observe: Portola Pharmaceuticals Inc Declines Again; Strong Momentum for Sellers

The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) is a huge mover today! About 1.24 million shares traded hands or 61.93% up from the average. Portola Pharmaceuticals Inc (NASDAQ:PTLA) has declined 22.84% since April 6, 2016 and is downtrending. It has underperformed by 24.79% the S&P500.
The move comes after 5 months negative chart setup for the $965.98M company. It was reported on Nov, 8 by Barchart.com. We have $14.89 PT which if reached, will make NASDAQ:PTLA worth $77.28 million less.

Analysts await Portola Pharmaceuticals Inc (NASDAQ:PTLA) to report earnings on November, 14. They expect $-1.11 EPS, down 5.71% or $0.06 from last year’s $-1.05 per share. After $-1.02 actual EPS reported by Portola Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 8.82% negative EPS growth.

Portola Pharmaceuticals Inc (NASDAQ:PTLA) Ratings Coverage

Out of 4 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 1 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 25% are positive. Portola Pharmaceuticals has been the topic of 11 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Portola Pharmaceuticals Inc (NASDAQ:PTLA) earned “Neutral” rating by Credit Suisse on Friday, August 19. The rating was maintained by Citigroup with “Buy” on Wednesday, August 10. The company was downgraded on Monday, March 28 by Goldman Sachs. Goldman Sachs initiated the stock with “Buy” rating in Friday, December 18 report. Citigroup maintained the stock with “Buy” rating in Friday, May 27 report. Citigroup downgraded the stock to “Neutral” rating in Friday, August 19 report. The stock has “Neutral” rating given by Credit Suisse on Tuesday, May 31. The company was maintained on Friday, August 19 by Morgan Stanley. Credit Suisse maintained the shares of PTLA in a report on Monday, March 28 with “Outperform” rating. The stock has “Buy” rating given by Cowen & Co on Wednesday, August 5.

According to Zacks Investment Research, “Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.”

Insitutional Activity: The institutional sentiment increased to 1.09 in Q2 2016. Its up 0.03, from 1.06 in 2016Q1. The ratio increased, as 26 funds sold all Portola Pharmaceuticals Inc shares owned while 43 reduced positions. 16 funds bought stakes while 59 increased positions. They now own 51.75 million shares or 1.93% less from 52.77 million shares in 2016Q1.
Numeric Limited Liability Corporation, a Massachusetts-based fund reported 209,300 shares. Blackrock Advsr Limited Liability has invested 0% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA). The New York-based Pinnacle Associates Ltd has invested 0.3% in Portola Pharmaceuticals Inc (NASDAQ:PTLA). Balyasny Asset Mgmt Ltd Liability Corporation accumulated 0.06% or 388,026 shares. Moreover, Blackrock has 0% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 5,257 shares. Proshare Advsr Ltd Company last reported 49,933 shares in the company. Valley National Advisers Inc holds 0% or 150 shares in its portfolio. Td Asset Mngmt owns 18,000 shares or 0% of their US portfolio. Sectoral Asset Incorporated last reported 3% of its portfolio in the stock. Rail reported 221,414 shares or 1.25% of all its holdings. Glenmede Na has 0% invested in the company for 1,000 shares. Fred Alger Mgmt Incorporated accumulated 95,842 shares or 0.01% of the stock. Moreover, Fisher Asset Management Ltd has 0% invested in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 82,737 shares. Fernwood Inv Ltd holds 5.39% of its portfolio in Portola Pharmaceuticals Inc (NASDAQ:PTLA) for 232,952 shares. Macquarie Gp Ltd accumulated 0% or 35,650 shares.

More notable recent Portola Pharmaceuticals Inc (NASDAQ:PTLA) news were published by: Seekingalpha.com which released: “Portola Pharmaceuticals’ (PTLA) CEO Bill Lis on Q3 2016 Results – Earnings …” on November 08, 2016, also Fool.com with their article: “Why Portola Pharmaceuticals Inc Is Plunging Today” published on August 18, 2016, Fool.com published: “Why Portola Pharmaceuticals, Inc. Increased 11.6% in April” on May 11, 2016. More interesting news about Portola Pharmaceuticals Inc (NASDAQ:PTLA) were released by: Fool.com and their article: “Why Portola Pharmaceuticals Inc’s Stock Is Bleeding Red Today” published on March 24, 2016 as well as Fool.com‘s news article titled: “Portola Pharmaceuticals: Does New Data Get It Back on Track?” with publication date: May 28, 2016.

PTLA Company Profile

Portola Pharmaceuticals, Inc., incorporated on September 2, 2003, is a biopharmaceutical company. The Firm is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. The Company’s third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Firm has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment